

Author Index Volume 23 (2011)

The issue number is given in front of the page numbers

- Abbott F.M., M.N. Graham Dukes, Global Pharmaceutical Policy – Ensuring medicines for tomorrow’s world (1) 43–49
- Abela, M., see Abou-Hussein, S. (4) 241–248
- Abou-Hussein, S., C. Savona-Ventura, S. Grima and A. Felice, Genetic factors in risk assessment for the development of type 2 diabetes mellitus in a small case series (2) 119–123
- Abou-Hussein, S., M. Abela and C. Savona-Ventura, Body Mass Index adjustment for sitting height for better assessment of obesity risks in Maltese women (4) 241–248
- Adeyemi, O.A., see Awodele, O. (4) 217–226
- Akhtar, S., see Saddichha, S. (3) 181–185
- Akinyede, A., see Awodele, O. (4) 217–226
- Anwikar, S.R., M.S. Bandekar, B. Smrati, A.P. Pazare, P.A. Tatke and N.A. Kshirsagar, HAART induced adverse drug reactions: A retrospective analysis at a tertiary referral health care center in India (3) 163–169
- Awodele, D.F., see Awodele, O. (4) 217–226
- Awodele, O., A. Akinyede, O.A. Adeyemi and D.F. Awodele, Pharmacovigilance amongst doctors in private hospitals in Lagos West Senatorial District, Nigeria (4) 217–226
- Bandekar, M.S., see Anwikar, S.R. (3) 163–169
- Bavdekar, S.B., see Gogtay, N.J. (1) 1–3
- Belefquih, B., see Tagajdid, M.R. (4) 249–254
- Bella, M.M., see Yousif, M.A. (1) 11–16
- Benabdallah, G., R., Benkirane, A., Khattabi, I.R., Edwards and R.S., Bencheikh, The involvement of Pharmacovigilance Centres in medication errors detection: A questionnaire-based analysis (1) 17–29
- Bencheikh, R.S., see Benabdallah, G. (1) 17–29
- Benkirane, R., see Benabdallah, G. (1) 17–29
- Bijl, D., H. Schellekens, The sponsored pandemic of the Mexican flu? (2) 73–79
- Bijl, D., Pandemic influenza vaccines and neuraminidase inhibitors: Efficacy and side effects (2) 65–71
- Body, D., I.R. Edwards, K.H. Go, and D. Healy, A. Herxheimer and J. Labadie, Is there a need for Forensic Pharmacovigilance as a specialty? (1) 31–42
- Breggin, P.R., Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for long-term treatment with psychiatric medication (4) 193–200
- Casalegno, J.S., see Tagajdid, M.R. (4) 249–254
- Chandler, P., A. Herxheimer, Unexpected aggressive behaviour: Interaction of bupropion and alcohol (3) 133–137
- Chopra, D., N. Wardhan and H.S. Rehan, Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital (4) 227–232

- Dewey, H., see Williams, L. (3) 139–147
 Doblali, T., see Tagajdid, M.R. (4) 249–254
- Edwards, I.R., see Benabdallah, G. (1) 17–29
 Edwards, I.R., see Body, D. (1) 31–42
 El Annaz, H., see Tagajdid, M.R. (4) 249–254
 Elmustafa, M.O., see Yousif, M.A. (1) 11–16
- Felice, A., see Abou-Hussein, S. (2) 119–123
- Go, K.H., see Body, D. (1) 31–42
 Gogtay, N.J., S.B. Bavdekar, Assessment of safety and tolerability of local application of DEBA cream in infants and children (1) 1–3
 Gøtzsche, P., see Nielsen, M. (2) 125–132
 Graham, M.N., see Abbott F.M. (1) 43–49
 Grima, S., see Abou-Hussein, S. (2) 119–123
- Hama, R., M. Jones, H. Okushima, M. Kitao, N. Noda, K. Hayashi and K. Sakaguchi, Oseltamivir and early deterioration leading to death: A proportional mortality study for 2009A/H1N1 influenza (4) 201–215
 Hassen, P., No. 5, October 2010, WHO Patient Safety Newsletter Progress in quality and patient safety: Are we at a tipping point? (1) 51–61
 Hayashi, K., see Hama, R. (4) 201–215
 Healy, D., Science, rhetoric and the causality of adverse events (3) 149–162
 Healy, D., see Body, D. (1) 31–42
 Henry, D., Doctors and drug companies: Still cozy after all these years (1) 7–10
 Herxheimer, A., see Ziganshina, L.E. (3) 187–192
 Hill, R., New vaccine reports from FDA to the Uppsala Monitoring Centre (2) 117–118
- Jones, M., see Hama, R. (4) 201–215
- Kapp, M.B., see Williams, L. (3) 139–147
 Khattabi, A., see Benabdallah, G. (1) 17–29
 Kitao, M., see Hama, R. (4) 201–215
 Kohler, J.C., see Lexchin, J. (4) 233–240
 Kshirsagar, N.A., see Anwikar, S.R. (3) 163–169
- Labadie, J., Postlicensure safety evaluation of human papilloma virus vaccines (2) 103–112
 Labadie, J., Vaccine safety news, (2) 113–115
 Lexchin, J., J.C. Kohler, The danger of imperfect regulation: OxyContin use in the United States and Canada (4) 233–240
- Marks, D.H., Neurological complications of vaccination with outer surface protein A (OspA) (2) 89–96
 Mekki, Y., see Tagajdid, M.R. (4) 249–254
 Menkes, D.B., see Ziganshina, L.E. (3) 187–192
 Mohiuddin, S., see Rajesh, R. (3) 171–180
 Mrani, S., see Tagajdid, M.R. (4) 249–254
 Mustafa, M.I., see Yousif, M.A. (1) 11–16
- Nielsen, M., P. Gøtzsche, An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products (2) 125–132

- Nizar, S., see Yousif, M.A. (1) 11–16
- Noda, N., see Hama, R. (4) 201–215
- Noorunnisa, see Rajesh, R. (3) 171–180
- Okushima, H., see Hama, R. (4) 201–215
- Pazare, A.P., see Anwikar, S.R. (3) 163–169
- Polyakova, I.P., see Sychev, D.A. (1) 5–6
- Rajesh, R., S. Vidyasagar, D.M. Varma, S. Mohiuddin and Noorunnisa, Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy (3) 171–180
- Rehan, H.S., see Chopra, D. (4) 227–232
- Saddichha, S., G. Vishnuvardhan and S. Akhtar, Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia (3) 181–185
- Sakaguchi, K., see Hama, R. (4) 201–215
- Savona-Ventura, C., see Abou-Hussein, S. (2) 119–123
- Savona-Ventura, C., see Abou-Hussein, S. (4) 241–248
- Schellekens, H., see Bijl, D. (2) 73–79
- Semenov, A.V., see Sychev, D.A. (1) 5–6
- Smrati, B., see Anwikar, S.R. (3) 163–169
- Sychev, D.A., A.V. Semenov and I.P. Polyakova, A case of hepatic injury suspected to be caused by Canephron N, a Centaurium Hill containing phytotherapeutics (1) 5–6
- Tagajdid, M.R., H. El Annaz, B. Belefquih, T. Doblali, J.S. Casalegno, Y. Mekki and S. Mrani, Factors influencing uptake of influenza vaccine amongst healthcare workers in a regional center after the A(H1N1) 2009 pandemic: Lessons for improving vaccination rates (4) 249–254
- Tatke, P.A., see Anwikar, S.R. (3) 163–169
- van Grootheest, A.C., see van Puijenbroek, E.P. (2) 81–87
- van Puijenbroek, E.P., A.C. van Grootheest, Monitoring adverse events of vaccines against Mexican flu (2) 81–87
- Varma, D.M., see Rajesh, R. (3) 171–180
- Viboud, C., L. Simonsen, Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? (2) 97–102
- Vidyasagar, S., see Rajesh, R. (3) 171–180
- Vishnuvardhan, G., see Saddichha, S. (3) 181–185
- Wardhan, N., see Chopra, D. (4) 227–232
- Williams, L., H. Dewey and M.B., Kapp, Long-term complication: Florida's death certification process and long-term care (3) 139–147
- Yousif, M.A., S. Nizar, M.O. Elmustafa, M.I. Mustafa and M.M. Bella, Investigation of medication prescribing errors in Wad Medani, Gezira, Sudan (1) 11–16
- Ziganshina, L.E., D.B. Menkes and A. Herxheimer, Quality information for quality use of medicines; 2nd International Conference, Kazan, 15–16 October 2010 (3) 187–192